HER2 positive breast cancer

• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Recruitment ended
  2023-507961-24-00 5 2021-04-19 "High-Risk HER2-Positive Breast Cancer"
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Recruitment ended
  2023-503568-18-00 5 2021-04-13 "Early human epidermal growth factor receptor 2 (HER2) positi"
• Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Recruitment ended
  2024-511204-16-00 5 2019-01-23 "Metastatic breast cancer"
• Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Recruitment ended
  2023-509923-42-00 4 2017-07-06 "HER2- positive breast cancer"
• An open-label extension study of pertuzumab administered on its own or in combination with other anti-cancer therapies in patients previousl … Recruitment ended
  2023-505102-42-00 5 2014-12-18 "Solid Malignant Tumors"
• A Study to Learn If The Study Medicine Called Fluconazole Changes How the Body Processes The Other Study Medicine PF-07248144 Ended
  2025-521924-31-00 3 2025-08-20 "locally advanced or metastatic HR+/HER2- breast cancer"
• A Phase 1 study to evaluate the metabolism of [14C]PF-07104091 in healthy adult male participants Ended
  2024-518696-65-00 3 2025-08-12 "(HR) -positive human epidermal growth factor receptor 2 (HER"
• Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer Ended
  2023-506866-30-00 4 2024-08-19 "HER2 positive or HER2-low metastatic breast cancer"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3 … Ended
  2023-505322-34-00 1 2024-01-08 "Advanced or metastatic solid tumors"
• Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients c … Ended
  2023-503627-26-00 4 2023-09-28 "Metastatic breast cancer"
• A Study to Estimate the Effect of Multiple Doses of Carbamazepine on the PK of Single Dose Vepdegestrant in Healthy Adult Participants Ended
  2023-505881-27-00 3 2023-08-14 "ER+/HER2 positive breast cancer"
• Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program) Ended
  2024-512826-26-00 4 2022-03-07 "Newly diagnosed, non-metastatic early-stage triple-negative "
• A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 … Ended
  2024-516289-12-00 9 2022-02-24 "Endometrial cancer, Ovarian cancer, Biliary tract cancer, He"
• A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr … Ended
  2024-514611-98-00 5 2021-07-20 "PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC)"
• APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer) Ended
  2023-506975-83-00 5 "HER2-positive metastatic breast cancer (MBC) and early breas"
• SPECT/CT imaging of FPI-2505 in patients with solid tumours; a phase 0 molecular imaging basket trial (SCOPE-study). Ended
  2025-521235-37-00 1 "small cell lung cancer, non-smallcell lung cancer, colorecta"

Showing 25–40 of 40 trials